drugset / Trial / NCT00002196

A Study of CI-1012 in HIV-Infected Patients

NCT00002196 ↗

Phase 1 Completed 32 enrolled Parke-Davis
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CI-1012 Unknown — Oral